Board Members

CDDF board members are distinguished and experienced pre-clinical and clinical investigators who are devoted to the development of cancer drugs. They have experience in giving advice or reviewing on drug development strategies in pre-clinical and early clinical development, designing phase I/IIl clinical trials using novel designs and endpoints to speed up and optimise the overall drug development programmes, and to avoid suboptimal drug development strategies.

• Prof. Leif Håkansson – Chairperson
• Prof. John Smyth – Deputy Chairperson
• Prof. Axel Glasmacher – CDDF Managing Director and Treasurer
• Prof. Jaap Verweij – Secretary
• Prof. Francesco De Lorenzo
• Prof. Max E. Scheulen